Screening rates were even lower (10.6%) in oncology patients.16 An international survey of the membership of the American Association for the Study of Liver Diseases reported that among 188 patients with HBVr, only 39.9% were screened for both HBsAg and anti-Hubs.15 In the current study, HBV screening rates were also very low and only 4.3% of the patients were screened for both HBsAg and anti-HBc IgG before starting IST. Here, KRT88P is linked to liver disorder.